Log In
BCIQ
Print this Print this
 

SNDX-6352 (formerly UCB6352)

  Manage Alerts
Collapse Summary General Information
Company UCB Group
Description mAb against colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)
Molecular Target Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerSyndax Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$374.5M

$5.0M

$369.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/06/2016

$374.5M

$5.0M

$369.5M

Get a free BioCentury trial today